💊 Cabergoline

Common side effects

The safety of Cabergoline Tablets has been evaluated in more than 900 patients with hyperprolactinemic disorders. Most adverse events were mild or moderate in severity. The incidence of the most common adverse events during the placebo-controlled study is presented in the following table. Pregnancy (label summary): Teratogenic Effects: Category B. Reproduction studies have been performed with cabergoline in mice, rats, and rabbits administered by gavage. These losses could be due to the prolactin inhibitory properties of cabergoline in rats. Breastfeeding (label summary): Nursing Mothers: It is not known whether this drug is excreted in human milk. General information only, not medical advice and not a prescription. No doses are given. Always consult a doctor or pharmacist before starting, stopping or changing any medicine, especially in pregnancy, breastfeeding, children, older age or with other medicines.